All In Biotech

Drug Trial Radar · NCT05593666

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Dec 27, 2022

Primary completion

Apr 15, 2025

Study completion Dec 22, 2025

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
Oct 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.

Conditions

  • Primary Visceral Leishmaniasis

Interventions

  • LXE408Drug

    Film-coated tablets

  • PlaceboOther

    Placebo film-coated tablets

  • AmBisome®Drug

    Sterile lyophilised powder in a 15 mL sterile clear glass vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with initial cure at Day 28 for LXE408Time frame: Day 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • DrugsNeglectedD Investigational Site

    Bihār, India

  • DrugsNeglectedD Investigational Site

    Patna, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.